Full name for licenses is Anthony Joseph ("A.J.") Cataldo II, PhD, CPA. Retired university accounting professor, CMA, CGMA and author of 10 books and 200+ articles and columns in 50+ different journals and outlets, with experience as CFO, Government Auditor, Public Accountant and Litigation Support Expert Witness in cases involving GM, Ford, and other big cap firms. Years ago, the Securities and Exchange Commission used 3 of my research articles in a fraud case. I have taught at 10 universities including No ...

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, "Pioneering the Economics of Health: Balancing Access and Outcomes," during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thoug ...

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thou ...

WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further expand company capabilities. As part of this leadership evolution: Tapan V Shah, Head of Investor Relations and Corporate Development, will take on added responsibil ...

WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company’s determination to advance its mission of developing accessible, life-saving therapeu ...

Core Insights - Tevogen Bio reported a significant reduction in net loss, decreasing from $56.8 million in 2023 to $4.3 million in 2024 for the nine months ended September 30 [1] - The company improved its financial position by nearly eliminating its liabilities, reporting $10.5 million as of September 30, 2024, down from $99.9 million as of December 31, 2023 [1][4] - Tevogen's intellectual property and product assets are valued internally at over $10 billion, but these are not reflected on the balance sheet due to US GAAP accounting rules [3][5] - The company has sufficient capital to fund operations for at least the next 33 months, supported by a loan agreement [4] Financial Performance - Tevogen's net loss for the nine months ended September 30, 2024, was $4.3 million, a significant improvement from $56.8 million in the same period of 2023 [1] - The company reported a substantial decrease in liabilities, from $99.9 million at the end of 2023 to $10.5 million by September 30, 2024 [1][4] Intellectual Property and Assets - Tevogen's internally developed intellectual property and product assets are valued at over $10 billion based on discounted cash flow models, but are not included on the balance sheet due to US GAAP restrictions [3][5] - The company holds multiple granted patents and has several pending patents related to its proprietary immunotherapy technologies and artificial intelligence platforms [6] Ownership Structure - Approximately 78% of equity is retained by Tevogen's officers, which is significantly higher than the industry average of 4% [5] - Key employees have also been granted substantial restricted stock units, reflecting a belief in shared ownership of the company's success [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share TVGN The Nasdaq Stock Market LLC Warrants, each exercisable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSIT ...

Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is considerably lower than the industry average [1][3] - The company focuses on off-the-shelf, genetically unmodified T cell therapeutics aimed at treating infectious diseases and cancers, emphasizing a disciplined and sustainable business model [2][4] - Tevogen's leadership is committed to preserving shareholder value while navigating the need for capital, with potential equity dilution from warrant conversion at a strike price of $11.50 per share, which could yield over $200 million [1][3] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for various diseases, addressing significant unmet medical needs [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier in medicine, necessitating innovative business models to sustain medical advancements [5]

Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is a fraction of the industry norm [1][3] - The company focuses on building a disciplined and sustainable business model in the biotech sector, particularly in immunotherapy for infectious diseases and cancers [2][4] - Tevogen's leadership emphasizes the importance of preserving shareholder value and being cautious about equity dilution when considering financing options [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified T cell therapies targeting infectious diseases, cancers, and neurological disorders [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating innovative business models to sustain medical innovation [5]

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen. In tandem with this announcement, Tevogen Bio reaffirms ...